| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2012PLoSO...738520L |
| P356 | DOI | 10.1371/JOURNAL.PONE.0038520 |
| P932 | PMC publication ID | 3466229 |
| P698 | PubMed publication ID | 23056165 |
| P5875 | ResearchGate publication ID | 232232752 |
| P50 | author | Herman S Overkleeft | Q39515014 |
| Marco van Eijk | Q57028127 | ||
| Johannes M F G Aerts | Q91978732 | ||
| Jan Aten | Q95986831 | ||
| Albert K Groen | Q107788097 | ||
| Roelof Ottenhoff | Q130271404 | ||
| Cindy P A A van Roomen | Q130271406 | ||
| Florence M Bietrix | Q130272197 | ||
| Elisa Lombardo | Q130280315 | ||
| P2093 | author name string | Arthur J Verhoeven | |
| Johan Kuiper | |||
| Gijs H van Puijvelde | |||
| P2860 | cites work | A simple method for the isolation and purification of total lipides from animal tissues | Q25939009 |
| Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity | Q28287290 | ||
| Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase | Q28474576 | ||
| Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses | Q28504769 | ||
| Regulation of hepatic lipogenesis by the transcription factor XBP1 | Q28507784 | ||
| Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes | Q28575190 | ||
| Long-term follow-up of patients with NAFLD and elevated liver enzymes | Q29620024 | ||
| Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance | Q30479891 | ||
| Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation | Q33420391 | ||
| Enhanced insulin sensitivity in mice lacking ganglioside GM3. | Q34870497 | ||
| Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. | Q35044164 | ||
| Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis | Q35268966 | ||
| Pathophysiology of nonalcoholic steatohepatitis | Q36422705 | ||
| Selective versus total insulin resistance: a pathogenic paradox | Q37076798 | ||
| Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis | Q37144593 | ||
| Animal models of NASH: getting both pathology and metabolic context right | Q37254525 | ||
| Non-alcoholic steatohepatitis and animal models: understanding the human disease. | Q37332814 | ||
| Glycosphingolipids and insulin resistance. | Q37419937 | ||
| Glycosphingolipids--nature, function, and pharmacological modulation. | Q37622816 | ||
| Nonalcoholic fatty liver disease: a review and update | Q37681360 | ||
| Role of endoplasmic reticulum stress in metabolic disease and other disorders. | Q37976132 | ||
| Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis | Q38310080 | ||
| Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease | Q38320784 | ||
| Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in APOE*3 Leiden and low-density lipoprotein receptor-/- mice | Q38346348 | ||
| Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation | Q38348150 | ||
| Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. | Q38350770 | ||
| A lipidomic screen of palmitate-treated MIN6 β-cells links sphingolipid metabolites with endoplasmic reticulum (ER) stress and impaired protein trafficking. | Q39603113 | ||
| Ameliorative effects of mulberry (Morus alba L.) leaves on hyperlipidemia in rats fed a high-fat diet: induction of fatty acid oxidation, inhibition of lipogenesis, and suppression of oxidative stress. | Q42780858 | ||
| Pioglitazone in the treatment of NASH: the role of adiponectin | Q42956360 | ||
| Hepatic glycosphingolipid deficiency and liver function in mice | Q43078747 | ||
| Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease | Q43094034 | ||
| Intake of 1-deoxynojirimycin suppresses lipid accumulation through activation of the beta-oxidation system in rat liver | Q43253579 | ||
| Hepatic monocyte chemoattractant protein-1 is upregulated by dietary cholesterol and contributes to liver steatosis | Q43277506 | ||
| Lipid composition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure | Q44470406 | ||
| Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis. | Q44925636 | ||
| Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. | Q46010720 | ||
| Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis | Q46455735 | ||
| Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation | Q47362663 | ||
| Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase | Q77359763 | ||
| Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man | Q79627193 | ||
| Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes | Q80241892 | ||
| Breath biomarkers and non-alcoholic fatty liver disease: preliminary observations | Q83966446 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | steatosis | Q1365091 |
| hydrophobicity | Q41854968 | ||
| P304 | page(s) | e38520 | |
| P577 | publication date | 2012-10-08 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Correction of liver steatosis by a hydrophobic iminosugar modulating glycosphingolipids metabolism | |
| P478 | volume | 7 |
| Q42175283 | Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase |
| Q38833111 | Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance |
| Q57047286 | Distinguishing the differences in beta-glycosylceramidase folds, dynamics, and actions informs therapeutic uses |
| Q60934934 | Glycoprotein Non-Metastatic Protein B: An Emerging Biomarker for Lysosomal Dysfunction in Macrophages |
| Q92191089 | Glycosphingolipids and Infection. Potential New Therapeutic Avenues |
| Q28552531 | Gpnmb Is a Potential Marker for the Visceral Pathology in Niemann-Pick Type C Disease |
| Q35561941 | In vitro identification of nonalcoholic fatty liver disease-related protein hnRNPM. |
| Q90604280 | Lipid rafts as a therapeutic target |
| Q50271402 | Lyso-glycosphingolipid abnormalities in different murine models of lysosomal storage disorders. |
| Q38244084 | The consequences of genetic and pharmacologic reduction in sphingolipid synthesis |
Search more.